A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NSCLC / non-small cell lung cancer

[Related PubMed/MEDLINE]
Total Number of Papers: 41275
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NSCLC  (>> Co-occurring Abbreviation)
Long Form:   non-small cell lung cancer
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study". IG, PA, QoL, SD, UC
2021 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer. 18F-FDG, CTCs, MTV-P, OS, PET/CT, PFS, TLG-P
2021 18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers. FDG, ICIs, OS, PET/CT, PMD, SMD, SUV
2021 18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. CT, PET, T2DM
2021 18F-labeled tracers targeting fibroblast activation protein. FAP
2021 18F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment. MTV, PFS, PreLMR, PreNLR, PrePLR, ROC, SUVpeak
2021 2,6-DMBQ suppresses cell proliferation and migration via inhibiting mTOR/AKT and p38 MAPK signaling pathways in NSCLC cells. 2,6-DMBQ
2021 20(S)-Ginsenoside Rg3 Inhibits Lung Cancer Cell Proliferation by Targeting EGFR-Mediated Ras/Raf/MEK/ERK Pathway. EGFR, qRT-PCR, SCLC, TKIs
2021 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study. CSC
10  2021 6-Color Crystal Digital PCRTM for the High-Plex Detection of EGFR Mutations in Non-Small Cell Lung Cancer. ctDNA
11  2021 9-O-Terpenyl-Substituted Berberrubine Derivatives Suppress Tumor Migration and Increase Anti-Human Non-Small-Cell Lung Cancer Activity. ---
12  2021 A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab. bTMB, OS, PDL1
13  2021 A bibliometric analysis of segmentectomy versus lobectomy for non-small cell lung cancer research (1992-2019). WoSCC
14  2021 A bivalent cyclic RGD-siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts. biRGD, VEGFR2
15  2021 A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. TIL, TME
16  2021 A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer. CCRT
17  2021 A Cascaded Neural Network for Staging in Non-Small Cell Lung Cancer Using Pre-Treatment CT. AUC, CNN, DL
18  2021 A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. ---
19  2021 A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency. ---
20  2021 A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. TKIs
21  2021 A case of the third-line treatment of lung adenocarcinoma using nivolumab combined with anlotinib. PD-L1
22  2021 A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer. EML4
23  2021 A circGLIS3/miR-644a/PTBP1 positive feedback loop promotes the malignant biological progressions of non-small cell lung cancer. circRNAs
24  2021 A circular network of coregulated sphingolipids dictates lung cancer growth and progression. ---
25  2021 A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab. AUC, OS
26  2021 A Combined Phytochemistry and Network Pharmacology Approach to Reveal Potential Anti-NSCLC Effective Substances and Mechanisms in Marsdenia tenacissima (Roxb.) Moon (Stem). ROS, TGT
27  2021 A Comparative Study of Cavitary and Noncavitary Non-small Cell Lung Cancer Patients Treated with CT-Guided Microwave Ablation. MW, OS, PFS
28  2021 A comprehensive comparison between young and older-age non-small cell lung cancer patients at a public referral centre in Delhi, India. ---
29  2021 A copper-free and enzyme-free click chemistry-mediated single quantum dot nanosensor for accurate detection of microRNAs in cancer cells and tissues. DBCO, FRET, LCR, miRNAs, QD
30  2021 A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. ICER, OS, PD-L1, PFS, QALYs
31  2021 A CRISPR/Cas13a-powered catalytic electrochemical biosensor for successive and highly sensitive RNA diagnostics. CHDC
32  2021 A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer. AUC, HR, OS, PFS
33  2021 A Cytoplasm-Enriched circRNA circ-MYBL2 is Downregulated in Non-Small Cell Lung Cancer and Sponges Oncogenic miR-28 to Regulate Cancer Cell Proliferation and Apoptosis. ---
34  2021 A Data Mining-Based Analysis of Core Herbs on Different Patterns (Zheng) of Non-Small Cell Lung Cancer. ---
35  2021 A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed Tomography Images. APE, CT, SM, SMI
36  2021 A Double-Edged Sword: The Anti-Cancer Effects of Emodin by Inhibiting the Redox-Protective Protein MTH1 and Augmenting ROS in NSCLC. MTH1, ROS
37  2021 A feedback circuit comprising EHD1 and 14-3-3ζ sustains β-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer. EHD1
38  2021 A framework for clinical and translational research in the era of rigor and reproducibility. CTR
39  2021 A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. CKs, CS, CTCs, EA, FDA, IVD, OS, PFS, SA
40  2021 A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models. ECD, EGFRs, TKIs
41  2021 A guided-inquiry investigation of genetic variants using Oxford nanopore sequencing for an undergraduate molecular biology laboratory course. NGS
42  2021 A innovative prognostic symbol based on neutrophil extracellular traps (NETs)-related lncRNA signature in non-small-cell lung cancer. lncRNA, NETs, OS
43  2021 A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer. NCCN, SEER
44  2021 A literature review on function and regulation mechanism of DKK4. CNVs, DKK4, EOC, GC, HCC, RCC, SNPs
45  2021 A Low Albumin-to-Globulin Ratio Predicts a Poor Prognosis in Patients With Metastatic Non-small-cell Lung Cancer. AGR, HR, OS, PFS
46  2021 A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma. ALK, LASSO, mRMR, ROC
47  2021 A Method for Liposome Co-encapsulation of Phenethyl Isothiocyanate and Cisplatin and Determining Its Toxicity Against Lung and Lung Cancer Cells. PEITC
48  2021 A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients. CI, OR, postFEV1, ppoFEV1
49  2021 A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914. cStage
50  2021 A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival. eQTL, SNPs
51  2021 A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. CI, TKIs
52  2021 A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-Small Cell Lung Cancer Patients. ROC
53  2021 A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player. PS, TKIs
54  2021 A narrative review of invasive diagnostics and treatment of early lung cancer. GGO, SBRT, VDT
55  2021 A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. ALK, EGFR, ICIs, ROS1, TKIs
56  2021 A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from in vitro studies. LC
57  2021 A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. TAMs
58  2021 A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. ICIs, LAT, MSCs, TAMs, TME
59  2021 A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses. CI, NCR
60  2021 A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. CrIs, ORR, OS, PD-L1, PFS
61  2021 A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies. ctDNA, EntroGen
62  2021 A Nomogram Based on CT Deep Learning Signature: A Potential Tool for the Prediction of Overall Survival in Resected Non-Small Cell Lung Cancer Patients. CT, HR, LASSO, NRI, OS
63  2021 A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy. C-index, NCDB, OS, SEER
64  2021 A nomogram for predicting the risk of lymph node metastasis in T1-2 non-small-cell lung cancer based on PET/CT and clinical characteristics. CEA, PET/CT
65  2021 A Nomogram to Predict Long-Term Survival Outcomes of Patients Who Undergo Pneumonectomy for Non-small Cell Lung Cancer With Stage I-IIIB. CSS, HR, PS
66  2021 A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. CNS, CSF, EGFR, LM, QD, SD
67  2021 A Noninvasive Assessment of Tumor Proliferation in Lung cancer Patients using Intravoxel Incoherent Motion Magnetic Resonance Imaging. AUROC, DKI, DWI, IHC, IVIM, LIs, MRI, ROC, SCLC
68  2021 A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. Abs, AUROC, PD-1
69  2021 A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients. ALK, FISH, NGS, PCR
70  2021 A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report. IBC, NGS, PET/CT
71  2021 A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer. ---
72  2021 A Novel Composite Biomarker Panel For Detection Of Early Stage Non-small Cell Lung Cancer. 4MPLA, AI, AUC, Ct, ROC
73  2021 A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. IMs, MICs
74  2021 A novel electrochemical lung cancer biomarker cytokeratin 19 fragment antigen 21-1 immunosensor based on Si3N4/MoS2 incorporated MWCNTs and core-shell type magnetic nanoparticles. CV, CYFRA21-1, EIS, FTIR, LOD, SEM, TEM, XPS, XRD
75  2021 A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report. EGFR, NGS, PFS, TKIs
76  2021 A novel lung autotransplantation technique for treating central lung cancer: a case report. ---
77  2021 A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. DTIP
78  2021 A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. EGFR-TKIs, STAT3
79  2021 A Novel Tumor Suppressor Gene, ZNF24, Inhibits the Development of NSCLC by Inhibiting the WNT Signaling Pathway to Induce Cell Senescence. TSGs
80  2021 A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib. EML4-ALK, TKIs
81  2021 A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report. PFS, SABR, SBRT, TPS
82  2021 A PCR-Based Approach for Driver Mutation Analysis of EGFR, KRAS, and BRAF Genes in Lung Cancer Tissue Sections. ---
83  2021 A PET/CT nomogram incorporating SUVmax and CT radiomics for preoperative nodal staging in non-small cell lung cancer. CI, LASSO, LN, mRMR, PET/CT, Rad-score, SAD
84  2021 A PET/CT volumetric parameter predicts prognosis of non-small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study. CCRT, MTV, PET/CT, PFS, TLG
85  2021 A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. OC, RP2D
86  2021 A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. RCC
87  2021 A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. DL1, DL2, ORR, PFS
88  2021 A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. AEs, NRG1, PK
89  2021 A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer. AEs, DCR, EGFR-TKIs, NKT, ORR, OS, PFS, TTP
90  2021 A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC). ---
91  2021 A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. PD-L1
92  2021 A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. DCR, ION, PR, RP2D
93  2021 A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). DFS, EGFR, ICI
94  2021 A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. AEs, CI, jRCT, ORR, OS, TRAEs
95  2021 A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. CNS, nab-P
96  2021 A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). BMRR, CNS, CSF, EGFR, PFS
97  2021 A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). EGFR, TKI
98  2021 A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation. CBCT
99  2021 A Pilot Study of Safer Radiation Dosage to the Heart and Its Subregions. DVH, GBV, HB, IMRT, VMAT
100  2021 A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer. ICIs, PFS